Nutra Pharma Sales Surge 77% Amid Deepening Losses, Liquidity Concerns

TL;DR

**Nutra Pharma's sales are up, but their financial hole is getting deeper, making it a high-risk bet on a turnaround that looks increasingly unlikely.**

AI Summary

NUTRA PHARMA CORP. reported a net loss of $1,035,346 for the six months ended June 30, 2025, an increase from a net loss of $794,073 in the prior year period. Despite this, net sales increased significantly, reaching $158,506 for the six months ended June 30, 2025, up from $89,442 in the same period of 2024, representing a 77.2% increase. Gross profit also rose to $143,959 from $90,042 year-over-year. However, selling, general, and administrative expenses surged to $784,307 from $604,844. The company's total assets increased to $859,068 as of June 30, 2025, from $599,495 at December 31, 2024, driven by increases in cash to $79,069 from $36,447 and other receivables. Total liabilities also grew to $16,692,328 from $15,407,409, with a significant working capital deficit of $15,888,753 and a stockholders' deficit of $15,833,260. The company continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and significant indebtedness.

Why It Matters

For investors, Nutra Pharma's significant sales growth in its pain relief products like Cobroxin and Nyloxin is a positive signal, but it's overshadowed by a widening net loss and a substantial working capital deficit. The company's reliance on debt and equity funding, coupled with its common stock being on the OTC Expert Market, severely limits its ability to raise capital and poses a high risk to its long-term viability. Employees and customers might face uncertainty if the company cannot secure additional financing to sustain operations and continue product development. Competitively, while the company is expanding its product lines, its financial instability could hinder its ability to compete effectively against larger, more financially robust pharmaceutical companies.

Risk Assessment

Risk Level: high — Nutra Pharma has an accumulated deficit of $77,266,483, a working capital deficit of $15,888,753, and a stockholders' deficit of $15,833,260 as of June 30, 2025. These figures, combined with recurring significant losses from operations and substantial indebtedness in default, indicate a severe liquidity crisis and raise substantial doubt about the company's ability to continue as a going concern.

Analyst Insight

Investors should exercise extreme caution and consider divesting any holdings in Nutra Pharma. The company's severe liquidity issues, recurring losses, and inability to access mainstream capital markets make it a highly speculative investment with significant downside risk. Wait for clear evidence of sustained profitability and a strengthened balance sheet before considering any investment.

Financial Highlights

debt To Equity

N/A

revenue

$158,506

operating Margin

N/A

total Assets

$859,068

total Debt

$16,692,328

net Income

-$1,035,346

eps

N/A

gross Margin

90.8%

cash Position

$79,069

revenue Growth

+77.2%

Key Numbers

• $1,035,346 — Net Loss (Increased from $794,073 for the six months ended June 30, 2024)
• $158,506 — Net Sales (Increased 77.2% from $89,442 for the six months ended June 30, 2024)
• $77,266,483 — Accumulated Deficit (As of June 30, 2025, indicating significant historical losses)
• $15,888,753 — Working Capital Deficit (As of June 30, 2025, highlighting severe short-term liquidity issues)
• $15,833,260 — Stockholders' Deficit (As of June 30, 2025, indicating negative equity)
• $79,069 — Cash (As of June 30, 2025, up from $36,447 at December 31, 2024, but still insufficient for operations)
• $16,692,328 — Total Liabilities (As of June 30, 2025, up from $15,407,409 at December 31, 2024)
• 7,159,727,214 — Common Stock Shares Outstanding (As of March 25, 2026)
• 12,000,000 — Series B Preferred Stock Shares Outstanding (As of March 25, 2026)
• $784,307 — Selling, General and Administrative Expenses (Increased from $604,844 for the six months ended June 30, 2024)

Key Players & Entities

• NUTRA PHARMA CORP. (company) — registrant and holding company
• ReceptoPharm, Inc. (company) — wholly-owned subsidiary conducting drug discovery
• Designer Diagnostics Inc. (company) — wholly-owned inactive subsidiary
• Cobroxin (product) — over-the-counter pain reliever
• Nyloxin (product) — over-the-counter pain reliever
• Pet Pain-Away (product) — over-the-counter pain reliever for animals
• Equine Pain-Away (product) — over-the-counter topical pain reliever for horses
• Luxury Feet (product) — over-the-counter pain reliever for foot pain
• Cell Defender (product) — zeolite detoxifier manufactured for a third party
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company faces substantial doubt about its ability to continue as a going concern due to recurring net losses, with a loss of $1,035,346 for the six months ended June 30, 2025, and a significant accumulated deficit of $77,266,483. This is exacerbated by a substantial working capital deficit of $15,888,753 and negative stockholders' equity of $15,833,260.
• Increasing Operating Expenses [high — financial]: Selling, general, and administrative expenses have surged to $784,307 for the six months ended June 30, 2025, from $604,844 in the prior year period. This increase outpaces the revenue growth, contributing to the widening net loss.
• Significant Indebtedness [high — financial]: Total liabilities have grown to $16,692,328 as of June 30, 2025, from $15,407,409 at December 31, 2024. This substantial debt burden, coupled with negative equity, poses a significant financial risk.
• Liquidity Constraints [high — operational]: Despite an increase in cash to $79,069 as of June 30, 2025, the company has a severe working capital deficit of $15,888,753. This indicates a critical shortage of liquid assets to meet short-term obligations.
• Revenue Growth vs. Profitability [medium — market]: While net sales increased by 77.2% to $158,506 for the six months ended June 30, 2025, the company's net loss widened to $1,035,346. This suggests that the current business model is not yet profitable despite sales traction.

Industry Context

The pharmaceutical and nutraceutical industries are highly competitive and subject to stringent regulatory oversight. Companies often face challenges in R&D, clinical trials, market penetration, and pricing pressures. Growth in the nutraceutical sector is driven by increasing consumer awareness of health and wellness, but also by intense competition and evolving scientific validation requirements.

Regulatory Implications

As a pharmaceutical company, Nutra Pharma Corp. is subject to extensive regulations from bodies like the FDA. Compliance with manufacturing standards (cGMP), product approvals, and marketing claims are critical. Failure to comply can result in significant fines, product recalls, and reputational damage, impacting its ability to operate and generate revenue.

What Investors Should Do

1. Monitor SG&A expense control
2. Assess path to profitability
3. Evaluate liquidity and debt management

Key Dates

• 2025-06-30: Six months ended June 30, 2025 — Reported a net loss of $1,035,346 on net sales of $158,506, with significant increases in SG&A expenses and total liabilities.
• 2024-06-30: Six months ended June 30, 2024 — Reported a net loss of $794,073 on net sales of $89,442, with SG&A expenses of $604,844.
• 2024-12-31: As of December 31, 2024 — Total assets were $599,495 and total liabilities were $15,407,409.

Glossary

Working Capital Deficit

Occurs when a company's current liabilities exceed its current assets, indicating a potential inability to meet short-term obligations. (Nutra Pharma Corp. has a significant working capital deficit of $15,888,753 as of June 30, 2025, highlighting severe short-term liquidity issues.)

Stockholders' Deficit

Represents negative shareholders' equity, meaning a company's liabilities exceed its assets. (Nutra Pharma Corp. has a stockholders' deficit of $15,833,260 as of June 30, 2025, indicating negative net worth.)

Going Concern

An assumption that a business will continue to operate for the foreseeable future, typically at least 12 months. (The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and significant indebtedness.)

Accumulated Deficit

The cumulative net losses of a company over its lifetime that have not been offset by net income. (Nutra Pharma Corp. has an accumulated deficit of $77,266,483 as of June 30, 2025, reflecting substantial historical unprofitability.)

Gross Profit

Revenue minus the cost of goods sold. (Gross profit increased to $143,959 for the six months ended June 30, 2025, from $90,042 in the prior year, indicating improved cost management on sales.)

Year-Over-Year Comparison

Compared to the prior year period, Nutra Pharma Corp. has demonstrated impressive revenue growth of 77.2%, with net sales reaching $158,506 for the six months ended June 30, 2025. However, this top-line growth has not translated into improved profitability, as the net loss widened from $794,073 to $1,035,346. A significant concern is the substantial increase in selling, general, and administrative expenses, which grew from $604,844 to $784,307, further pressuring margins. The company's financial position remains precarious, with a growing working capital deficit and continued doubt about its going concern status.

Filing Documents

• form10-q.htm (10-Q) — 1354KB
• ex31-1.htm (EX-31.1) — 19KB
• ex32-1.htm (EX-32.1) — 7KB
• 0001493152-26-012625.txt ( ) — 9312KB
• nphc-20250630.xsd (EX-101.SCH) — 62KB
• nphc-20250630_cal.xml (EX-101.CAL) — 73KB
• nphc-20250630_def.xml (EX-101.DEF) — 275KB
• nphc-20250630_lab.xml (EX-101.LAB) — 460KB
• nphc-20250630_pre.xml (EX-101.PRE) — 376KB
• form10-q_htm.xml (XML) — 1474KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION F-1

Financial Statements

Item 1. Financial Statements F-1 Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 F-1 Condensed Consolidated Statements of Operations for the Three and Six months ended June 30, 2025 and 2024 (Unaudited) F-2 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Three months ended June 30, 2025 and 2024 (Unaudited) F-3 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Six months ended June 30, 2025 and 2024 (Unaudited) F-4 Condensed Consolidated Statements of Cash Flows for the Six months ended June 30, 2025 and 2024 (Unaudited) F-5 Notes to Condensed Consolidated Financial Statements (Unaudited) F-6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 4

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 9

Controls and Procedures

Item 4. Controls and Procedures 9

OTHER INFORMATION

PART II. OTHER INFORMATION 10

Legal Proceedings

Item 1. Legal Proceedings 10

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 11

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 11

Mine Safety Disclosure

Item 4. Mine Safety Disclosure 11

Other Information

Item 5. Other Information 11

Exhibits

Item 6. Exhibits 11 2 Nutra Pharma Corp ("Nutra Pharma") and its wholly owned subsidiaries, Designer Diagnostics Inc. and ReceptoPharm, Inc. ("ReceptoPharm"), are referred to herein as "we", "our" or "us" (Designer Diagnostics Inc. has been inactive since June 2011, ReceptoPharm is also individually referred to herein). Forward Looking Statements This Quarterly Report on Form 10–Q for the period ending June 30, 2025, contains forward–looking statements that involve risks and uncertainties, as well as assumptions that if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward–looking statements. The words or phrases "would be," "will allow, "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward–looking statements." We are subject to risks detailed in Item 1(a). All statements other than statements of historical fact are statements that could be deemed forward–looking statements, including: (a) any projections of revenue, gross margin, expenses, earnings or losses from operations, synergies or other financial items; and (b) any statements of the plans, strategies and objectives of management for future operations; and (c) any statement concerning developments, plans, or performance. Unless otherwise required by applicable law, we do not undertake and we specifically disclaim any obligation to update any forward–looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. 3 PART I. FINANCIAL INFORMATION Item 1. Financial Statements NUTRA PHARMA CORP. Condensed Consolidated Balance Sheets June 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets: Cash $ 79,069 $ 36,447 Accounts receivable 35,224 23,755 Accounts receivable - related party, net 9,455 5,800 Accou

View Full Filing

View this 10-Q filing on SEC EDGAR